The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids

Hormone Molecular Biology and Clinical Investigation

Volumn 1, Issue 2, 2010, Pages 95-102

  Dušková, Michaela ^a   Hill, Martin ^a   Stárka, Luboslav ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

5 reductase; androgenetic alopecia; anxiety; depression; finasteride; neuroactive steroid

Indexed keywords

16ALPHA HYDROXYDEHYDROEPIANDROSTERONE; 16ALPHA HYDROXYPREGNENOLONE; 17 HYDROXYPREGNENOLONE; 3BETA HYDROXY 5BETA PREGNAN 20 ONE; 5 ANDROSTENE 3BETA,7BETA,17BETA TRIOL; 5BETA ANDROSTAN 3ALPHA,17BETA DIOL; 5BETA ANDROSTANOLONE; 7 OXO DEHYDROEPIANDROSTERONE; 7 OXO PREGNENOLONE; 7ALPHA HYDROXYDEHYDROEPIANDROSTERONE; 7ALPHA HYDROXYPREGNENOLONE; 7BETA HYDROXYDEHYDROEPIANDROSTERONE; 7BETA HYDROXYPREGNENOLONE; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENDIOL; ANDROSTENE 3BETA,7ALPHA,17BETA TRIOL; ANDROSTERONE; BREXANOLONE; ELTANOLONE; EPIANDROSTERONE; ESTRADIOL; ETIOCHOLANOLONE; FINASTERIDE; ISOPREGNAOLONE; PRASTERONE; PREGNENOLONE; SEPRANOLONE; SEX HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LOW DRUG DOSE; MALE; MALE TYPE ALOPECIA; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY; TREATMENT DURATION;

EID: 85021082879     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.010     Document Type: Article

References (22)

1. Rahimi-Ardabili B., Pourandarjani R., Habibollahi P., Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol 2006;6:7-13.
2. Ciotta L., Cianci A., Calogero AE., Marletta E., Sciuto A., Palumbo G. Clinical and endocrine effects of finasteride., a 5 alpha-reduc-tase inhibitor., in women with idiopathic hirsutism. Fertil Steril 1995;64:299-306.
3. Moinpour CM., Lovato LC., Thompson IM Jr., Ware JE Jr., Ganz PA., Patrick DL., Shumaker SA., Donaldson GW., Ryan A., Coltman CA Jr. Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life., urinary and sexual functioning., and health behaviours. J Clin Oncol 2000;18:1942-53.
4. Altomare G., Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Der-matol 2002;29:665-9.
5. Finn DA., Beasles-Bohling AS., Becley EH., Ford MM., Gilland KR., Gorin-Meyer RE., Wiren KM. A new look at the 5α-reduc-tase inhibitor finasteride. CNS Drug Rev 2006;12:53-76.
6. Lepkart ED., Husmann DA. Altered brain and pituitary androgen metabolism by prenatal., perinatal or postnatal finasteride., fluta-mide dihydrotestosterone treatment in juvenile rats. Prog Neu-ropsychopharmacol Biol Psychiatry 1993;17:991-1003.
7. Hirani K., Khisti RT., Chopde CT. Behavioural action of ethanol in Porsolt's forced swim test: modulation by 3 alpha-hydroxy-5 alpha-pregnan-20-one. Neuropharmacology 2002;43:1339-50.
8. Frye CA., Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behaviour of proestrous rats. Horm Behav 2002;41:305-15.
9. Walf AA., Sumida K., Frye CA. Inhibiting 5alpha-reductase in the amygdala attenuates antianxiety and antidepressive behaviour of naturally receptive and hormone-primed ovariectomized rats. Psychopharmacology (Berl) 2006;186:302-11.
10. Murphy NP., Sakoori K., Okabe C. Lack of evidence of a role for the neurosteroid allopregnanolone in ethanol-induced reward and c-fos expression in DBA/2 mice. Brain Res 2006;1094: 107-18.
11. De Brito Faturi C., Teixeira-Silva F., Leite JR. The anxiolytic effect of pregnancy in rats reversed by finasteride. Pharmacol Biochem Behav 2006;85:569-74.
12. Beckley EH., Finn DA. Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility. Pharmacol Biochem Behav 2007;87:412-9.
13. Izumi Y., Murayama K., Tokuda K., Krishnan K., Covey DF., Zorumski CF. GABAergic neurosteroids mediate the effects of ethanol on long-term potentiation in rat hippocampal slices. Eur J Neurosci 2007;26:1881-8.
14. Uemura M., Tamura K., Chung S., Honma S., Okuyama A., Naka-mura Y., Nakagawa H. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81-6.
15. Sudduth SL., Koronkowaki MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy 1993;13:309-25.
16. Kaufman KD., Dawber RP. Finasteride., a type 2 5α-reductase inhibitor., in the treatment of men with androgenetic alopecia. Exp Opin Invest Drug 1999;8:403-15.
17. Mondaini N., Gontero P., Giubilei G., Lombardi G., Cai T., Gavazzi A., Bartoletti R. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007;4:1708-12.
18. Collodel G., Scapigliati G., Moretti E. Spermatozoa and chronic treatment with finasteride: a TEM and FISH study. Arch Androl 2007;53:229-33.
19. Liu KE., Binsaleh S., Lo KC., Jarvi K. Propecia-induced sper-matogenic failure: a report of two cases. Fertil Steril 2008; 90:849, e17-9.
20. Al-Harbi TM., Kagan J., Tarnopolsky MA. Finasteride-induced myalgia and HyperCKemia. J Clin Neuromuscul Dis 2008;10: 76-8.
21. Issa SA., Dagres E. Intraoperative floppy-iris syndrome and finasteride intake. J Cataract Refract Surg 2007;33:2142-3.
22. Martínez de Guzman M., Martínez-Crespo JJ. Finasteride-induced hepatitis. Farm Hosp 2006;30:385.